This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2017-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2022
Title: Innovations of Yoshihisa Kobayashi
Introduction
Yoshihisa Kobayashi is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of three patents. His work focuses on the development of novel compounds that have potential therapeutic applications.
Latest Patents
Kobayashi's latest patents include innovative compounds represented by specific formulas. One of his patents involves pentacyclic heterocycles, which provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof. Another patent focuses on pentacyclic compounds, offering compounds represented by formulas (1) to (VI) or pharmaceutically acceptable salts thereof. These inventions reflect his commitment to advancing pharmaceutical science.
Career Highlights
Yoshihisa Kobayashi is currently associated with Eisai R&D Management Co., Ltd., where he continues to contribute to research and development in the pharmaceutical industry. His expertise and innovative mindset have positioned him as a valuable asset in his field.
Collaborations
Kobayashi has collaborated with notable colleagues, including Yoshiaki Ohashi and Yu Yoshida. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Yoshihisa Kobayashi's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations highlight his dedication to advancing medical science and improving therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile